Approved and investigational uses of modafinil: An evidence-based review

Drugs

Volumn 68, Issue 13, 2008, Pages 1803-1839

  Kumar, Raminder ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Circadian rhythm sleep disorders, treatment; Modafinil, general; Narcolepsy, treatment; Sleep apnoea syndrome, treatment

Indexed keywords

AMPHETAMINE; ANTIHISTAMINIC AGENT; CAFFEINE; CENTRAL STIMULANT AGENT; CORTICOSTEROID; CYCLOSPORIN; DEXAMPHETAMINE; ETHINYLESTRADIOL; FLUOXETINE; HISTAMINE H2 RECEPTOR ANTAGONIST; METHYLPHENIDATE; MODAFINIL; PLACEBO; SERTRALINE; TRIAZOLAM; WARFARIN;

ANESTHETIC RECOVERY; ANXIETY DISORDER; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CATAPLEXY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE DEFECT; DECREASED APPETITE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DISEASE MODEL; DISEASE SEVERITY; DIZZINESS; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FATIGUE; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; INSOMNIA; IRRITABILITY; MANIA; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MITRAL VALVE PROLAPSE; MOOD; MULTIPLE SCLEROSIS; MUSCLE TONE; MYOTONIC DYSTROPHY; NARCOLEPSY; NAUSEA; NERVOUSNESS; NONHUMAN; PARKINSON DISEASE; PLACEBO EFFECT; POSITIVE END EXPIRATORY PRESSURE; POSTPOLIOMYELITIS SYNDROME; PSYCHOSIS; RESTLESSNESS; REVIEW; RHINITIS; SCHIZOPHRENIA; SHIFT WORK SLEEP DISORDER; SHIFT WORKER; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SLEEP APNEA SYNDROME; SLEEP DEPRIVATION; SLEEP DISORDER; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; SYMPTOM; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREMOR; WEIGHT REDUCTION;

BENZHYDRYL COMPOUNDS; DRUG APPROVAL; EVIDENCE-BASED MEDICINE; HUMANS; NARCOLEPSY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WAKEFULNESS;

EID: 50249113719     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868130-00003     Document Type: Review

References (165)

1. National Sleep Foundation. Omnibus sleep in America poll. Washington, DC: National Sleep Foundation, 2001
2. Hasler G, Buysse DJ, Gamma A, et al. Excessive daytime sleepiness in young adults: a 20-year prospective community study. J Clin Psychiatry 2005; 66: 521-9
3. Pilcher JJ, Huffcutt AI. Effects of sleep deprivation on performance: a meta-analysis. Sleep 1996 May; 19 (4): 318-2
4. Dinges DF, Pack F, Williams K, et al. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4-5 hours per night. Sleep 1997 Apr; 20 (4): 267-77
5. Van Dongen HP, Maislin G, Mullington JM, et al. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 2003 Mar 15; 26 (2): 117-26
6. NHTSA. National Highway Traffic Safety Administration report [online]. Available from URL: http://www.nhtsa.gov/people/injury/research/drowsy_driver. html [Accessed 2006 Apr 25]
7. Leger D. The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research. Sleep 1994 Feb; 17 (1): 84-93
8. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005 Oct 27; 437 (7063): 1257-63
9. Fuller PM, Gooley JJ, Saper CB. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback. J Biol Rhythms 2006 Dec; 21 (6): 482-93
10. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008 Jun; 33 (7): 1477-502
11. Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994 Aug; 17: 436-7
12. De Séréville JE, Boer C, Rambert FA, et al. Lack of pre-synaptic dopaminergic involvement in modafinil activity in anaesthetized mice: in vivo voltammetry studies. Neuropharmacology 1994 Jun; 33: 755-61
13. Simon P, Hémet C, Ramassamy C, et al. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 1995 Dec; 5 (4): 509-14
14. Akaoka H, Roussel B, Lin JS, et al. Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett 1991 Feb 11; 123 (1): 20-2
15. Duteil J, Rambert FA, Pessonnier J, et al. Central alpha 1- adrenergic stimulation in relation to the behaviour stimulating effect of modafinil: studies with experimental animals. Eur J Pharmacol 1990 May 3; 180 (1): 49-58
16. Lin JS, Roussel B, Akaoka H, et al. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 1992 Sep 25; 591 (2): 319-26
17. Eagle DM, Tufft MR, Goodchild HL, et al. Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol. Psychopharmacology (Berl) 2007 Jun; 192 (2): 193-206
18. de Saint Hilaire Z, Orosco M, Rouch C, et al. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 2001 Nov 16; 12 (16): 3533-7
19. Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21: 1787-94
20. Murillo-Rodriguez E, Haro R, Palomero-Rivero M, et al. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res 2007 Jan 25; 176 (2): 353-7
21. Dopheide MM, Morgan RE, Rodvelt KR, et al. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol 2007 Jul 30; 568 (1-3): 112-23
22. Korotkova TM, Klyuch BP, Ponomarenko AA, et al. Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors. Neuropharmacology 2007 Feb; 52 (2): 626-33
23. Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006 Nov; 319 (2): 561-9
24. Mignot E, Renaud A, Nishino S, et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl) 1993; 113 (1): 76-82
25. Nishino S, Fruhstorfer B, Arrigoni J, et al. Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J Pharmacol Exp Ther 1993 Mar; 264 (3): 1079-84
26. Gallopin T, Luppi PH, Rambert FA, et al. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 2004 Feb 1; 27 (1): 19-25
27. Stone EA, Cotecchia S, Lin Y, et al. Role of brain alpha 1B-adrenoceptors in modafinil-induced behavioral activity. Synapse 2002 Dec 15; 46 (4): 269-70
28. Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005; 132: 1027-34
29. Ferraro L, Antonelli T, O'Connor WT, et al. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 1997 Sep 8; 8 (13): 2883-7
30. Ferraro L, Antonelli T, O'Connor WT, et al. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 1998 Sep 4; 253 (2): 135-8
31. Ferraro L, Tanganelli S, O'Connor WT, et al. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 1996 Dec 6; 220: 5-8
32. A receptor blockade. Neuropsychopharmacology 1999 Apr; 20 (4): 346-56
33. Tanganelli S, Fuxe K, Ferraro L, et al. Inhibitory effects of the psychoactive drug modafinil on γ-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea pig: possible involvement of 5-hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol 1992; 345: 461-5
34. Tanganelli S, Ferraro L, Bianchi C, et al. 6-Hydroxy-dopamine treatment counteracts the reduction of cortical GABA release produced by the vigilance promoting drug modafinil in the awake freely moving guinea-pig. Neurosci Lett 1994 Apr 25; 171 (1-2): 201-4
35. Tanganelli S, Pérez de la Mora M, Ferraro L, et al. Modafinil and cortical gamma-aminobutyric acid outflow: modulation by 5-hydroxytryptamine neurotoxins. Eur J Pharmacol 1995 Jan 24; 273 (1-2): 63-71
36. Ferraro L, Tanganelli S, O'Connor WT, et al. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996 Jun 13; 306: 33-9
37. Ferraro L, Antonelli T, O'Connor WT, et al. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 1997 Dec 15; 42 (12): 1181-3
38. Ferraro L, Fuxe K, Tanganelli S, et al. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 2000 Aug 23; 39 (11): 1974-83
39. Ferraro L, Fuxe K, Tanganelli S, et al. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res 2002 Apr 1; 68 (1): 107-12
40. Ferraro L, Fuxe K, Agnati L, et al. Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: a dual probe microdialysis study in awake rat. Synapse 2005 Mar 15; 55 (4): 230-41
41. Nishino S. The hypocretin/orexin system in health and disease. Biol Psychiatry 2003 Jul 15; 54 (2): 87-95
42. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999 Aug 20; 98 (4): 437-51
43. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000 Nov 15; 20 (22): 8620-8
44. Willie JT, Renthal W, Chemelli RM, et al. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience 2005; 130 (4): 983-95
45. Ishizuka T, Sakamoto Y, Sakurai T, et al. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 2003 Mar 20; 339 (2): 143-6
46. Ishizuka T, Murakami M, Yamatodani A. Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats. Eur J Pharmacol 2008 Jan 14; 578 (2-3): 209-15
47. Lagarde D, Milhaud C. Electroencephalographic effects of modafinil, an alpha-1- adrenergic psychostimulant, on the sleep of rhesus monkeys. Sleep 1990 Oct; 13: 441-8
48. Shelton J, Nishino S, Vaught J, et al. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995 Dec; 18: 817-26
49. Touret M, Sallanon-Moulin M, Jouvet M. Awakening properties of modafinil without paradoxical sleep rebound: comparative study with amphetamine in the rat. Neurosci Lett 1995 Apr 7; 189: 43-6
50. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hyper5 somnolence in the rat. J Pharmacol Exp Ther 1997 Nov; 283: 757-69
51. Panckeri KA, Schotland HM, Pack AI, et al. Modafinil decreases hypersomnolence in the English bulldog, a natural animal model of sleep-disordered breathing. Sleep 1996 Oct; 19: 626-31
52. Lin JS, Gervasoni D, Hou Y, et al. Effects of amphetamine and modafinil on the sleep/wake cycle during experimental hypersomnia induced by sleep deprivation in the cat. J Sleep Res 2000 Mar; 9 (1): 89-96
53. Turner DC, Robbins TW, Clark L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 2003; 165: 260-9
54. Baranski JV, Pigeau R, Dinich P, et al. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 2004 Jul; 19 (5): 323-32
55. Müller U, Steffenhagen N, Regenthal R, et al. Effects of modafinil on working memory processes in humans. Psychopharmacology 2004; 177: 161-9
56. Makris AP, Rush CR, Frederich RC, et al. Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults. Exp Clin Psychopharmacol 2007 Apr; 15 (2): 123-33
57. Randall DC, Shneerson JM, Plaha KK, et al. Modafinil affects mood, but not cognitive function, in healthy young volunteers. Hum Psychopharmacol 2003; 18: 163-73
58. Randall DC, Fleck NL, Shneerson JM, et al. The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers. Pharmacol Biochem Behav 2004; 77: 547-55
59. Randall DC, Viswanath A, Bharania P, et al. Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived? J Clin Psychopharmacol 2005; 25: 175-9
60. Taneja I, Haman K, Shelton RC, et al. A randomized, double-blind, crossover trial of modafinil on mood. J Clin Psychopharmacol 2007 Feb; 27 (1): 76-9
61. Lagarde D, Batejat D. Disrupted sleep-wake rhythm and performance: advantages of modafinil. Mil Psychol 1995; 7: 165-91
62. Pigeau R, Naitoh P, Buguet A, et al. Modafinil, d-amphetamine and placebo during 64h of sustained mental work. I, effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 1995; 4: 212-28
63. Stivalet P, Esquivie D, Barraud P-A, et al. Effects of modafinil on attentional processes during 60h of sleep deprivation. Hum Psychopharmacol 1998; 13: 501-7
64. Wesensten NJ, Belenky G, Kautz MA, et al. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology 2002; 159: 238-47
65. Wesensten NJ, Belenky G, Thorne DR, et al. Modafinil vs. caffeine: effects on fatigue during sleep deprivation. Aviat Space Environ Med 2004 Jun; 75 (6): 520-5
66. Wesensten NJ, Killgore WD, Balkin TJ. Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 2005 Sep; 14 (3): 255-66
67. Dinges DF, Arora S, Darwish M, et al. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006 Jan; 22 (1): 159-67
68. Lagarde D, Batejat D, Van Beers P, et al. Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment. Fundam Clin Pharmacol 1995; 9 (3): 271-9
69. Walsh JK, Randazzo AC, Stone KL, et al. Modafinil improves alertness, vigilance, and executive function during simulated night shifts. Sleep 2004 May 1; 27 (3): 434-9
70. Hart CL, Haney M, Vosburg SK, et al. Modafinil attenuates disruptions in cognitive performance during simulated night-shift work. Neuropsychopharmacology 2006 Jul; 31 (7): 1526-36
71. Saletu B, Frey R, Krupka M, et al. Differential effects of a new adrenergic agonist: modafinil and D-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharmacol Res 1989; 9 (3): 183-95
72. Saletu B, Frey R, Krupka M, et al. Differential effects of the new adrenergic agonist modafinil and D-amphetamine on sleep and early morning behaviour in elderlies. Arzneimittelforschung 1989; 39 (10): 1268-73
73. Robertson PR, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42 (2): 123-7
74. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999 Jan; 39 (1): 30-40
75. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999 Mar; 39 (3): 281-8
76. Moachon G, Kanmacher I, Clenet M, et al. Pharmacokinetic profile of modafinil. Drugs Today 1996; 32: 327-37
77. Cephalon Inc. Provigil (modafinil) tablets: prescribing information [online]. Available from URL: http://www.provigil.com/ [Accessed 2007 Feb 22]
78. Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep 1994 Dec; 17 (8 Suppl.): S107-12
79. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998 Jan; 43 (1): 88-97
80. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000 Mar 14; 54 (5): 1166-75
81. Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997; 49: 444-51
82. Schwartz JR, Feldman NT, Bogan RK, et al. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol 2003 Sep-Oct; 26 (5): 252-7
83. Schwartz JR, Nelson MT, Schwartz ER, et al. Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness [published erratum appears in Clin Neuropharmacol 2004 May-Jun; 27 (3): 152]. Clin Neuropharmacol 2004 Mar-Apr; 27 (2): 74-9
84. Guilleminault C, Abad VC. Obstructive sleep apnea syndromes. Med Clin North Am 2004 May; 88 (3): 611-30
85. Kingshott RN, Vennelle M, Coleman EL, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual daytime excessive sleepiness in the sleep apnea/hypopneac syndrome. Am J Respir Crit Care Med 2001; 163: 918-23
86. Pack AI, Black JE, Schwartz JRL, et al. Modafinil as adjunct therapy for daytime sleepiness in the obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164: 1675-81
87. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 2005 Apr 1; 28 (4): 464-71
88. Dinges D, Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Medicine 2003; 4: 393-402
89. Beers TM. Flexible schedules and shift work: replacing the '9-to-5' workday? Monthly Labor Rev 2000; 123: 33-40
90. Drake CL, Roehrs T, Richardson G, et al. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep 2004 Dec 15; 27 (8): 1453-62
91. Czeisler CA, Walsh JK, Roth T, et al., for the U.S. Modafinil in Shift Work Sleep Disorder Study Group. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 2005 Aug 4; 353 (5): 476-86
92. Erman MK, Rosenberg R, for the US Modafinil Shift Work Sleep Disorder Study Group. Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life. Prim Care Companion J Clin Psychiatry 2007; 9 (3): 188-94
93. Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005 Dec; 76 (12): 1636-9
94. Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled trial. Sleep 2002; 25: 905-9
95. Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Movement Disorders 2003; 18: 287-93
96. Laberge L, Bégin P, Montplaisir J, et al. Sleep complaints in patients with myotonic dystrophy. J Sleep Res 2004 Mar; 13 (1): 95-100
97. MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002; 59: 1876-80
98. Talbot K, Stradling J, Crosby J, et al. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromuscul Disord 2003; 13: 357-64
99. Wintzen AR, Lammers GJ, van Dijk JG. Does modafinil enhance activity of patients with myotonic dystrophy? A double-blind placebo-controlled crossover study. J Neurol 2007 Jan; 254 (1): 26-8
100. Jha A, Weintraub A, Allshouse A, et al. A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury. J Head Trauma Rehabil 2008 Jan-Feb; 23 (1): 52-63
101. Visser SN, Lesesne CA. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder: United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 54 (34): 842-7
102. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005 Dec; 116 (6): e777-84
103. Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006 Jan; 67 (1): 137-47
104. Greenhill LL, Biederman J, Boellner SW, et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 May; 45 (5): 503-11
105. DuPaul G, Power T, Anastopoulos A, et al. ADHD rating scale-IV: home and school versions. New York: Guilford Publications, 1998
106. Conners CK. Conners' parent rating scales-revised: short form (CPRS-R:S). North Tonawanda (NY): Multi-Health Systems, 1997
107. Gresham FM, Elliot SN. Social skills rating scale. Circle Pines (MN): American Guidance Service, 1990
108. Landgraf JM, Abetz L, Ware JE. The child health questionnaire (CHQ): a user's manual. Boston (MA): Health Act, 1999
109. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Psychopharmacologic Drugs Advisory Committee Meeting: March 2006 [online]. Available from URL: http://www.fda.gov/ ohrms/dockets/ac/06/transcripts/2006-4212T1.pdf [Accessed 2007 Feb 24]
110. Biederman J, Swanson JM, Wigal SB, et al. Modafinil ADHD Study Group. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry 2006 May; 67 (5): 727-35
111. Conners CK, Sitarenios G, Parker JD, et al. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998 Aug; 26 (4): 257-68
112. Amiri S, Mohammadi MR, Mohammadi M, et al. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 2008 Jan 1; 32 (1): 145-9
113. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006 Feb; 36 (2): 159-65
114. Moss SB, Nair R, Vallarino A, et al. Attention deficit/hyperactivity disorder in adults. Prim Care 2007 Sep; 34 (3): 445-73
115. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000; 10 (4): 311-20
116. Murphy KR, Barkley RA. Updated adult norms for the ADHD Behavior Checklist for Adults. ADHD Report 1996; 4: 12-13
117. Barkley RA, Murphy KR. Attention-deficit hyperactivity disorder: a clinical workbook. New York (NY): Guilford Press, 1998: 131-3
118. Golden CJ. Identification of brain disorders by the Stroop Color and Word Test. J Clin Psychol 1976; 32: 654-8
119. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602
120. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005 Jan; 66 (1): 85-93
121. DeBattista C, Dogramji K, Menza MA, et al. Adjunct modafinil for short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64: 1057-64
122. Dunlop BW, Crits-Christoph P, Evans DL, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2007 Dec; 27 (6): 614-9
123. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007 Aug; 164 (8): 1242-9
124. Rush AJ, Giles DE, Schlesser MA. The Inventory of Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1986; 18: 65-87
125. Turner DC, Clark L, Pomarol-Clotet E, et al. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004 Jul; 29 (7): 1363-73
126. Sevy S, Rosenthal MH, Alvir J, et al. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 2005 Jul; 66 (7): 839-43
127. Spence SA, Green RD, Wilkinson ID, et al. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry 2005 Jul; 187: 55-61
128. Pierre JM, Peloian JH, Wirshing DA, et al. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry 2007 May; 68 (5): 705-10
129. Cambridge Neuropsychological Test Automated Battery (CANTAB®) [online]. Available from URL: http:// www.cantab.com [Accessed 2007 Nov 1]
130. Callicott JH, Ramsey NF, Tallent K, et al. Functional magnetic resonance brain mapping in psychiatry: methodological issues illustrated in a study of working memory in schizophrenia. Neuropsychopharmacology 1998; 18: 186-96
131. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988; 24: 97-9
132. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Br J Psychiatry 1989; 155 Suppl. 7: 53-8
133. Guy W, editor. ECDEU assessment manual for psychopharmacology. US Dept Health, Education and Welfare publication (ADM): Rockville (MD): National Institute of Mental Health, 1976: 76-338
134. Simpson GM, Lee JH, Zoubok B, et al. A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 1979; 64: 171-9
135. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-9
136. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L. The continuous performance test, identical pairs version: II, contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res 1989 Jul; 29 (1): 65-85
137. Cornblatt BA, Obuchowski M, Roberts S, et al. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 1999; 11: 487-508
138. Gold JM, Carpenter C, Randolph C, et al. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997 Feb; 54 (2): 159-65
139. Hershey T, Craft S, Glauser TA, et al. Short-term and long-term memory in early temporal lobe dysfunction. Neuropsychology 1998 Jan; 12 (1): 52-64
140. Lezak MD. Neuropsychological assessment. Third edition. New York (NY): Oxford University Press, 1995: 438-45, 544-50
141. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982 Jul; 39 (7): 784-8
142. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005 Jan; 30 (1): 205-11
143. Hart CL, Haney M, Vosburg SK, et al. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008 Mar; 33 (4): 761-8
144. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Allen J, Litten RZ, editors. Measuring alcohol consumption: psychosocial and biological medthods. Totowa (NJ): Humana Press, 1992: 41-72
145. Kampman KM, Volpicelli JR, McGinnis DE, et al. Reliability and validity of the cocaine selective severity assessment. Addict Behav 1998; 23: 449-61
146. Somoza E, Dyrenforth S, Goldsmith J, et al. In search of a universal drug craving scale. Annual Meeting of the American Psychiatric Association; 1995 May 20-25; Miami (FL)
147. Tiffany ST, Singleton E, Haertzen CA, et al. The development of a cocaine craving questionnaire. Drug Alcohol Depend 1993; 34: 19-28
148. Randall DC, Cafferty FH, Shneerson JM, et al. Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. J Psychopharmacol 2005 Nov; 19 (6): 647-60
149. Chan KM, Strohschein FJ, Rydz D, et al. Randomized controlled trial of modafinil for the treatment of fatigue in post-polio syndrome. Muscle Nerve 2006 Jan; 33 (1): 138-41
150. Vasconcelos OM, Prokhorenko OA, Salajegheh MK, et al. Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. Neurology 2007 May 15; 68 (20): 1680-6
151. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. French Modafinil Study Group. Neurology 2005 Apr 12; 64 (7): 1139-43
152. Larijani GE, Goldberg ME, Hojat M, et al. Modafinil improves recovery after general anesthesia. Anesth Analg 2004 Apr; 98 (4): 976-81
153. Gill M, Haerich P, Westcott K, et al. Cognitive performance following modafinil versus placebo in sleep-deprived emergency physicians: a double-blind randomized crossover study. Acad Emerg Med 2006 Feb; 13 (2): 158-65
154. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000 Mar; 14 (1): 53-60
155. Martin WR, Sloan JW, Sapira JD, et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971 Mar-Apr; 12 (2): 245-58
156. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004 Apr; 25 (4): 193-200
157. Robertson P, DeCory HH, Madan A, et al. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000 Jun; 28 (6): 664-71
158. Robertson Jr P, Hellriegel ET, Arora S, et al. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol 2002 Feb; 42 (2): 205-14
159. Robertson Jr P, Hellriegel ET, Arora S, et al. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther 2002 Jan; 71 (1): 46-56
160. FDA. Provigil® (modafinil) tablets (C-IV) [online]. Available from URL: http://www.fda.gov/cder/foi/label/2004/20717se1-008_provigil_lbl.pdf [Accessed 2007 Mar 3]
161. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005 May 26; 352 (21): 2211-21
162. Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist 2006 Feb; 11 (2): 126-35
163. Mariani JJ, Hart CL. Psychosis associated with modafinil and shift work [letter]. Am J Psychiatry 2005 Oct; 162 (10): 1983
164. Narendran R, Young CM, Valenti AM, et al. Is psychosis exacerbated by modafinil? Arch Gen Psychiatry 2002 Mar; 59 (3): 292-3
165. Sabatine MS, Poh KK, Mega JL, et al. Case records of the Massachusetts General Hospital: case 36-2007 -a 31-year-old woman with rash, fever, and hypotension. N Engl J Med 2007 Nov 22; 357 (21): 2167